Brookfield Infrastructure Partners LP vs Boston Scientific Corporation — how do they compare? Brookfield Infrastructure Partners LP trades at $38.19 (market cap $17.38B), while Boston Scientific Corporation trades at $42.73 (market cap $66.37B). The key difference: Boston Scientific Corporation is far larger — about 3.8× Brookfield Infrastructure Partners LP's market cap, and Brookfield Infrastructure Partners LP pays a 4.77% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BIP | BSX | |
|---|---|---|
Market Cap | $17.38B | $66.37B |
Sector | Industrials | Health |
52-Week High | $40.08 | $108.14 |
52-Week Low | $29.81 | $42.63 |
Enterprise Value | $79.06B | $75.94B |
Dividend Yield | 4.77% | — |
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $37.61, down slightly by 0.11% today. The stock shows bullish technical signals with strong analyst support (81% buy ratings) and a $45.50 consensus price target. Recent earnings have been mixed with one beat and two misses, but the company maintains robust cash flows with $5.97B from operations in 2025. BIP offers a 5% dividend yield with recent H1-26 payment of $0.46 per share.
BIP presents a compelling value opportunity with discounted valuation metrics (P/S 0.73, EV/EBITDA 7.55) and strong infrastructure assets. However, investors face risks from recent earnings volatility, high P/E ratio of 57.8, and declining profit margins. The company's global infrastructure portfolio provides inflation protection and stable cash flows, supporting the bullish analyst consensus despite near-term headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →